Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830
Debt
Debt-to-Equity RatioN/A
Current Ratio60.95
Quick Ratio60.95
Price-To-Earnings
Trailing P/E Ratio-16.71
Forward P/E Ratio-24.49
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.83 per share
Price / Book5.12
Profitability
EPS (Most Recent Fiscal Year)($1.48)
Net Income$-7,920,000.00
Net MarginsN/A
Return on Equity-23.26%
Return on Assets-22.75%
Miscellaneous
Employees12
Outstanding Shares10,980,000
Market Cap$182.02 million
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) released its quarterly earnings data on Monday, August, 6th. The company reported ($0.22) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.12. View Krystal Biotech's Earnings History.
When is Krystal Biotech's next earnings date?
What price target have analysts set for KRYS?
5 brokers have issued twelve-month target prices for Krystal Biotech's shares. Their predictions range from $35.00 to $38.00. On average, they expect Krystal Biotech's share price to reach $35.8750 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price. View Analyst Price Targets for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (10/17/2018)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and increasing our price target to $35/share from $28/share on Krystal Biotech. This morning, Krystal announced and held a conference call to discuss interim results from two patients in the ongoing Phase 1/2 study (GEM) of KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). The trial met all primary efficacy endpoints for the two patients and showed substantial improvements in time to wound closure, in our view. Importantly, KB103 was well tolerated with no serious adverse events or product- related adverse events reported. Krystal remains on track to complete the study in 1H19." (10/15/2018)
- 3. Chardan Capital analysts commented, "We note the addition of Mr. Maheu is in line with Krystal’s commitment to establishing in-house manufacturing capabilities. The company confirmed its cGMP facility is on target to be completed by 4Q18, which is in line with previous guidance. Krystal has previously indicated it expects the facility to become operational in 1Q19. The phase I/II trial (NCT03536143) of KB103 in dystrophic epidermolysis bullosa is also on track, with 2 patients currently enrolled. The company affirmed this trial will read out both safety and efficacy data in 4Q18. Additionally, Krystal held a pre-IND meeting with the FDA to discuss its 2nd asset, KB105, in TGM-1-deficient autosomal recessive congenital ichthyosis. As previously stated, the company plans to file the IND in 4Q18. We see continued execution on guidance to be a positive for Krystal." (8/6/2018)
- 4. William Blair analysts commented, "We anticipate a catalyst rich second half of the year for the company with interim safety and efficacy results from the Phase I/II DEB trial and an IND filing for KB105 in the fourth quarter . In addition, Krystal continues to focus on manufacturing with the completion of a GMP facility for clinical grade products anticipated in the fourth quarter as well as the recent hiring of a vice president of process development and manufacturing operations with Imlygic experience, Amgen’s (AMGN $199.22; Market Perform) HSV-1-based product approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery (backbone similarity to Krystal’s ST AR-D platform)." (8/6/2018)
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Novavax (NVAX), Scholar Rock (SRRK), Voyager Therapeutics (VYGR), Vericel (VCEL), Nightstar Therapeutics (NITE), NanoString Technologies (NSTG), La Jolla Pharmaceutical (LJPC), Replimune Group (REPL), Translate Bio (TBIO), CASI Pharmaceuticals (CASI), PDL BioPharma (PDLI), Adverum Biotechnologies (ADVM), MeiraGTx (MGTX), Cellular Biomedicine Group (CBMG) and Surface Oncology (SURF).
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 53)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 39)
- Mr. Antony A. Riley, Chief Financial Officer (Age 51)
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $24.73.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $182.02 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.
What is Krystal Biotech's official website?
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
